A systematic approach to the reporting of medically relevant findings from whole genome sequencing

[1]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[2]  Eric Vilain,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[3]  J. Simard,et al.  Medical Genetic Counseling for Breast Cancer in Primary Care: A Synthesis of Major Determinants of Physicians' Practices in Primary Care Settings , 2014, Public Health Genomics.

[4]  Leslie G Biesecker,et al.  Diagnostic clinical genome and exome sequencing. , 2014, The New England journal of medicine.

[5]  Isaac S Kohane,et al.  The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine , 2014, Trials.

[6]  Euan A Ashley,et al.  Clinical interpretation and implications of whole-genome sequencing. , 2014, JAMA.

[7]  T. Beery.  Genetic and Genomic Testing in Clinical Practice: What You Need to Know , 2014, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.

[8]  R. Saul,et al.  Genetic services and attitudes in primary care pediatrics , 2014, American journal of medical genetics. Part A.

[9]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[10]  Trevor J Pugh,et al.  A systematic approach to assessing the clinical significance of genetic variants , 2013, Clinical genetics.

[11]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[12]  Matthew S. Lebo,et al.  A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record , 2013, Genetics in Medicine.

[13]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[14]  D. Jordan,et al.  Large Numbers of Genetic Variants Considered to be Pathogenic are Common in Asymptomatic Individuals , 2013, Human mutation.

[15]  A. Folsom,et al.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls , 2013, European Journal of Epidemiology.

[16]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[17]  Jessie H. Conta,et al.  Practices and Policies of Clinical Exome Sequencing Providers: Analysis and Implications , 2013, American Journal of Medical Genetics. Part A.

[18]  Robert C. Green,et al.  Clinical Genome Sequencing , 2013 .

[19]  J. Stoller,et al.  A review of α1-antitrypsin deficiency. , 2012, American journal of respiratory and critical care medicine.

[20]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[21]  K. Jablonski,et al.  The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program , 2012, Diabetes Care.

[22]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.

[23]  Vineet Bafna,et al.  Exome Sequencing Can Improve Diagnosis and Alter Patient Management , 2012, Science Translational Medicine.

[24]  Kelly Schoch,et al.  Clinical application of exome sequencing in undiagnosed genetic conditions , 2012, Journal of Medical Genetics.

[25]  Heidi L. Rehm,et al.  Communicating new knowledge on previously reported genetic variants , 2012, Genetics in Medicine.

[26]  P. Ellinor,et al.  Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. , 2012, Heart rhythm.

[27]  D. Jaffe,et al.  Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing , 2012, Science Translational Medicine.

[28]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[29]  Elaine Lyon,et al.  The GeneInsight suite: a platform to support laboratory and provider use of DNA‐based genetic testing , 2011, Human mutation.

[30]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[31]  J. Kujovich.  Factor V Leiden thrombophilia , 2011, Genetics in Medicine.

[32]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[33]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[34]  M. Tulinius,et al.  Unexpected myopathy associated with a mutation in MYBPC3 and misplacement of the cardiac myosin binding protein C , 2009, Journal of Medical Genetics.

[35]  D. English,et al.  HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis‐related morbidity , 2009, Hepatology.

[36]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[37]  P. Bendahl,et al.  Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels , 2009, BMC Medical Genetics.

[38]  N. Milman,et al.  Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants , 2009, Annals of Hematology.

[39]  Kyung-A Lee,et al.  Cataloging Coding Sequence Variations in Human Genome Databases , 2008, PloS one.

[40]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[41]  A. Hofman,et al.  Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration , 2008, Pharmacogenetics and genomics.

[42]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[43]  C. Willer,et al.  Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations , 2008, Diabetologia.

[44]  M. McCarthy,et al.  Common variants in WFS1 confer risk of type 2 diabetes , 2007, Nature Genetics.

[45]  R. L. Lekanne Deprez,et al.  Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene , 2006, Journal of Medical Genetics.

[46]  M. Vidaud,et al.  Three point mutations in the CFTR gene in French cystic fibrosis patients: Identification by denaturing gradient gel electrophoresis , 1990, Human Genetics.

[47]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[48]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[49]  Miyuki Kimura,et al.  Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.

[50]  J. Olynyk,et al.  A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. , 2002, Gastroenterology.

[51]  J. Koziol,et al.  Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA , 2002, The Lancet.

[52]  S. Jacobson,et al.  CNGA3 mutations in hereditary cone photoreceptor disorders. , 2001, American journal of human genetics.

[53]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Higashi,et al.  Evidence of an increased risk of hearing loss in heterozygous carriers in a Wolfram syndrome family , 1998, Human Genetics.

[55]  M H Doolittle,et al.  Molecular characterization of human hepatic lipase deficiency. In vitro expression of two naturally occurring mutations. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[56]  N. Raben,et al.  A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). , 1993, The Journal of biological chemistry.

[57]  B. Kerem,et al.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. , 1992, American journal of human genetics.

[58]  A. Hamosh,et al.  Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. , 1991, The Journal of clinical investigation.

[59]  R. Hegele,et al.  Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. , 1991, Biochemical and biophysical research communications.

[60]  F. Collins,et al.  Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.